Brief summary of the agreement
Anyone is free:
· to copy, distribute, and display the work;
· to make derivative works;
· to make commercial use of the work;
Under the following conditions: Attribution
· the original author must be given credit;
· for any reuse or distribution, it must be made clear to others what the license terms of this work are;
· any of these conditions can be waived if the authors gives permission.
Statutory fair use and other rights are in no way affected by the above
Author Biographies
Neila Fathallah
Resident of Clinical Pharmacology, Department of Clinical Pharmacology, Faculty of Medicine of Sousse, Tunisia
Zayani Hanen
Emergency Health Technician, Intensive Care Department, Sahloul Hospital, Sousse, Tunisia
Raoudha Slim
Resident of Clinical Pharmacology, Department of Clinical Pharmacology, Faculty of Medicine of Sousse, Tunisia
Lobna Boussofara
Assistant professor of Dermatology, Farhat Hached University Hospital, Sousse, Tunisia
Ghariani Najet
Assistant professor of Dermatology, Farhat Hached University Hospital, Sousse, Tunisia
Kamel Bouraoui
Resident of Clinical Pharmacology, Department of Clinical Pharmacology, Faculty of Medicine of Sousse, Tunisia
Chaker Ben Salem
Resident of Clinical Pharmacology, Department of Clinical Pharmacology, Faculty of Medicine of Sousse, Tunisia
Main Article Content
Co-amoxiclav-induced Stevens Johnson Syndrome in a child
Neila Fathallah
Zayani Hanen
Raoudha Slim
Lobna Boussofara
Ghariani Najet
Kamel Bouraoui
Chaker Ben Salem
Abstract
Stevens-Johnson Syndrome is an uncommon life threatening disease generally induced by drugs. Antibiotics, mainly sulphonamides, are the most involved drugs in Stevens-Johnson Syndrome in children. Co-amoxiclav is a well tolerated antibiotic. It has never been reported to cause, lonely this syndrome in children. Herein, we report a co-amoxiclav-induced Stevens-Johnson Syndrome occurring in an 18-month-old child. The diagnosis of SJS is often challenging in children and other possible diseases should be ruled out. The etiology of this syndrome is not yet fully understood. It is thought to be mediated by an immunologic mechanism. Management involves early identification, withdrawal of the culprit drug and rapid initiation of supportive therapies.
Pan African Medical Journal 2013; 14:38
Donate
AJOL is a Non Profit Organisation that cannot function without donations.
AJOL and the millions of African and international researchers who rely on our free services are deeply grateful for your contribution.
AJOL is annually audited and was also independently assessed in 2019 by E&Y.
Your donation is guaranteed to directly contribute to Africans sharing their research output with a global readership.
Once off donations here:
For annual AJOL Supporter contributions, please view our Supporters page.
Tell us what you think and showcase the impact of your research!
Please take 5 minutes to contribute to our survey so that we can better understand the contribution that African research makes to global and African development challenges. Share your feedback to help us make sure that AJOL's services support and amplify the voices of researchers like you.